AbbVie (ABBV) stock has gained 19.4% in the past three months compared with an increase of 8.1% for the industry. The stock has also outperformed the sector and S&P 500 index as seen in the chart below.ABBV Stock Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchThe stock has also been consistently trading above its 50-day and 200-day moving averages since early July.The price increase in the past three months was mainly driven by AbbVie’s strong second-quarter results wherein it ...

AbbVie NYSE: ABBV is a global biopharmaceutical company long synonymous with its blockbuster drug, Humira. While the drug's success has propelled AbbVie to great heights, its recent patent expiration has greatly influenced the company's future.While the "Humira cliff" is undeniably significant, a closer look reveals a company that has proactively prepared for this moment, building a diversified portfolio and strategic roadmap for continued growth. For the right investors, AbbVie presents a compelling case o ...

29 April 2024, Rhineland-Palatinate, Ludwigshafen: Malu Dreyer, Minister President of ... [+] Rhineland-Palatinate, speaks at the official ground-breaking ceremony for the construction of a new research and development building on the premises of the pharmaceutical company AbbVie. Photo: Uwe Anspach/dpa (Photo by Uwe Anspach/picture alliance via Getty Images)dpa/picture alliance via Getty ImagesAbbVie stock (NYSE: ABBV) has more than doubled in value since early January 2021 - jumping from levels of $90 the ...

文章核心观点 - 在经济衰退期间,投资者可以考虑投资一些能够相对良好表现的公司,如拥有稳定股息的公司[1] - 医疗保健行业被认为是防御性行业,因为医疗产品和服务并非奢侈品,而是人们健康所需[2] - 制药公司AbbVie和Merck是两家可以帮助投资者度过最严峻经济衰退的公司[1] 关于AbbVie - AbbVie的主要业务是制药,拥有多种治疗领域的重要药品[2] - 尽管AbbVie的主打药物Humira专利到期,但公司的财务业绩仍然不错,收入增长4.3%[3] - AbbVie通过收购和内部研发来丰富产品线,其主要增长驱动力Skyrizi和Rinvoq预计到2027年将带来超过270亿美元收入[4] - AbbVie连续52年增加派息,目前股息收益率超过3.16%,在经济衰退期间仍能维持收入和盈利,保持股息支付[4] 关于Merck - Merck的头号销售药物Keytruda成为全球最畅销药物,仍有很大增长空间[5] - 尽管Keytruda专利将于2028年到期,但Merck正在开发皮下注射剂型以延长其专利期,并有其他新药物支撑[5][6] - Merck过去10年股息增长75%,目前股息收益率为2.65%,经济衰退不太可能打断其业务和股息支付[6]

A drugmaker and a telecom business have what it takes to safely boost your passive income stream.Did you know that September is generally a lousy month for the stock market? Individual investors and hedge fund managers tend to take profits they've gained over the summer or sell off any losers to lower their taxable income.This September, the Federal Reserve is widely expected to reduce interest rates. Rate reductions tend to raise markets but investors have been expecting this one for over a year. In other ...

These businesses can stand the test of time in a diversified portfolio.Many investors are worried about a resurgence of turbulence in the markets and what that could mean for stocks in the weeks and months ahead. But great businesses can withstand the test of time and provide meaningful portfolio returns. Concerns about the U.S. economy, its impact on the global economy, and the trickle-down impact of inflation on businesses across industries are legitimate.At the same time, if you're investing your cash in ...

These three have secure core businesses, plus multiple paths to grow.Almost every portfolio needs a couple of anchor stocks that tend to grow consistently over time regardless of the mood of the market or the state of the economy. Thanks to the must-buy nature of lifesaving medicines and the regular launch of new and improved drugs, pharma stocks are a good place to look for the anchors that might be right for you.In that vein, there are three rock-solid pharma stocks in particular that are strong enough to ...

During times of market volatility, it’s always good for long-term investors to take a breath and zoom out. That doesn’t mean getting out of the markets as fast as possible. Instead, it means looking back at the past performance of the stocks they own or those on their watchlist(s).  While it’s true that you want to look for stock price growth, you also want to invest in companies that have a history of increasing revenue and earnings. This growth helps to ensure that a company can sustain a higher stock pri ...

文章核心观点 - 艾利利利公司(Eli Lilly)的新药物tirzepatide在治疗肥胖、2型糖尿病等疾病方面取得了巨大成功,销售额超过10亿美元 [4] - tirzepatide还可能在治疗阻塞性睡眠呼吸暂停和心力衰竭等疾病方面获得监管机构的批准 [5] - 艾利利利公司正在研究将tirzepatide与其他药物如Taltz联合用于治疗银屑病等免疫性疾病,这可能会对阿博特公司(AbbVie)的业务产生影响 [7][8][9] - 虽然目前tirzepatide在免疫性疾病领域的应用还需要一些时间,但其跨入免疫领域的潜力巨大,可能会对阿博特公司的主导地位构成挑战 [10][11][12] 公司相关 - 艾利利利公司的研发工作仍在持续,正在探索将tirzepatide与其他药物联合用于治疗更多疾病 [6][9] - 艾利利利公司正在加大对tirzepatide的研发投入,希望进一步拓展其适应症 [6] - 艾利利利公司的tirzepatide可能会对阿博特公司的主导地位构成挑战,但这种影响还需要一些时间 [13][14] - 艾利利利公司的一些扩展tirzepatide适应症的尝试可能会失败,需要关注哪些尝试可能带来最大的财务影响 [15] 行业相关 - tirzepatide跨入免疫性疾病领域的潜力巨大,可能会对阿博特公司的主导地位产生影响 [10][11][12] - 诺和诺德公司的药物semaglutide也显示出可能有助于治疗银屑病的潜力,与tirzepatide的作用机制相似 [8] - 阿博特公司的主导产品Humira专利保护期已经结束,市场份额正在被仿制药快速侵蚀 [10] - 阿博特公司开发的替代Humira的新药Skyrizi和Rinvoq在免疫性疾病领域的覆盖范围与Humira大致相同 [11]

amphotora/E+ via Getty Images Introduction On May 29, I wrote an article titled "Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered." Since then, shares of the Abbott Laboratories (ABT) spin-off have returned roughly 30%, beating the S&P 500 by 23 points. Since becoming independent in April 2012, AbbVie Inc. (NYSE:ABBV) has returned 810%, beating both the S&P 500 and the healthcare ETF (XLV). Data by YCharts Although I'm obviously happy, my thesis has turned out to be correct, it's impor ...